Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas P Restifo

Showing results (211-220 of 260) with videos related to

Pageof 26
Sort By:
Journal of Translational Medicine|March 17, 2012
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancerDavid F Stroncek, Carolina Berger, Martin A Cheever, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimensMark E Dudley, James C Yang, Richard Sherry, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2003
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaGiao Q Phan, James C Yang, Richard M Sherry, et al.
The Journal of Experimental Medicine|November 4, 2015
Cish actively silences TCR signaling in CD8+ T cells to maintain tumor toleranceDouglas C Palmer, Geoffrey C Guittard, Zulmarie Franco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanomaJohn F Toso, Vee J Gill, Patrick Hwu, et al.
JCI Insight|December 8, 2017
Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapyChristopher A Klebanoff, Joseph G Crompton, Anthony J Leonardi, et al.
Journal for Immunotherapy of Cancer|November 30, 2025
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery CommitteeGeorge Coukos, Marco Donia, Brian R Gastman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanomaLing Zhang, Richard A Morgan, Joal D Beane, et al.
Science (New York, N.Y.)|September 21, 2002
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytesMark E Dudley, John R Wunderlich, Paul F Robbins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanomaMark E Dudley, Colin A Gross, Robert P T Somerville, et al.
Pageof 26

Showing results (211-220 of 260) with videos related to

Sort By:
Pageof 26
Journal of Translational Medicine|March 17, 2012
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancerDavid F Stroncek, Carolina Berger, Martin A Cheever, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimensMark E Dudley, James C Yang, Richard Sherry, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2003
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaGiao Q Phan, James C Yang, Richard M Sherry, et al.
The Journal of Experimental Medicine|November 4, 2015
Cish actively silences TCR signaling in CD8+ T cells to maintain tumor toleranceDouglas C Palmer, Geoffrey C Guittard, Zulmarie Franco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanomaJohn F Toso, Vee J Gill, Patrick Hwu, et al.
JCI Insight|December 8, 2017
Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapyChristopher A Klebanoff, Joseph G Crompton, Anthony J Leonardi, et al.
Journal for Immunotherapy of Cancer|November 30, 2025
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery CommitteeGeorge Coukos, Marco Donia, Brian R Gastman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanomaLing Zhang, Richard A Morgan, Joal D Beane, et al.
Science (New York, N.Y.)|September 21, 2002
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytesMark E Dudley, John R Wunderlich, Paul F Robbins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanomaMark E Dudley, Colin A Gross, Robert P T Somerville, et al.
Pageof 26